family with sequence similarity 95 member B1Genealiases: []
Q-omics provides the consensus-scored FAM95B1 profile across patient tissues and cancer cell-line models. FAM95B1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, FAM95B1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, FAM95B1 RNA expression shows 16,212 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, COAD, and UVM as cancer lineages where FAM95B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM95B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM95B1 survival associations across molecular data types. FAM95B1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM95B1 RNA expression–survival associations across cancer types. High FAM95B1 expression shows unfavorable associations in LGG, UVM, THCA, KIRC and LUAD, but favorable associations in BRCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for FAM95B1 RNA expression.
This table summarizes FAM95B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM95B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM95B1 shows lower tumor expression in COAD, THCA, HNSC, LUAD and BRCA and higher tumor expression in KIRP. The COAD box plot shows higher FAM95B1 RNA expression in normal versus tumor tissue (log2 FC = −0.049, t-test p < 0.001).
This table shows molecular features associated with FAM95B1 in patient tissues and cancer cell lines. In patient samples, FAM95B1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
